Eagle Pharmaceuticals, the predominantly 505(b)(2) hybrid new drug application player, says it is open to further development for complex abbreviated new drug application products, as the US-based firm awaits regulatory review for its proposed generic of Endo’s $700m Vasostrict (vasopressin) injectable.
The US Food and Drug Administration has now granted priority review for Eagle’s ANDA product, following the company’s response to...




